COMPARISON BETWEEN TWO DIFFERENT CLOPIDOGREL MAINTENANCE DOSES

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 在经皮介入治疗后增加氯吡格雷的维持量将导致对血小板聚集的抑制增加。这项研究的主要目的是测试氯吡格雷的维持量从每天75毫克增加到150毫克是否会额外抑制ADP诱导的血小板聚集。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Increasing the maintenance dose of clopidogrel following a percutaneous intervention will result in increased suppression of platelet aggregation. The main goal of this study is to test whether an increase of the maintenance dose of clopidogrel from 75 to 150 mg per day results in an additional suppresion of ADP-induced platelet aggregation.